药物对比
Saxagliptin vs Pioglitazone
Saxagliptin vs Pioglitazone：DPP-4抑制剂 vs 噻唑烷二酮类治疗2型糖尿病。比较心力衰竭风险、体重增加、水肿、胰岛素抵抗和副作用。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when type 2 diabetes patients on metformin require add-on oral therapy and must balance DPP-4 incretin effects against TZD insulin-sensitizing benefits amid cardiovascular and fluid-retention concerns.
结论
Saxagliptin generally suits patients prioritizing weight neutrality and lower edema risk, while Pioglitazone may be considered for significant insulin resistance, with neither inherently superior and selection based on individual risk profiles.
全部药物对比